Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05811754 · ClinicalTrials.gov registry record
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
A clinical trial of Herpes Zoster, sponsored by GlaxoSmithKline.
- Active
- Registry status
- 2,844
- Enrollment target
- 1
- Study location
NCT05811754: Active study of Herpes Zoster, sponsored by GlaxoSmithKline.
NCT05811754 is a study of Herpes Zoster that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 2,844 participants, above the 1,996-participant average among 16 other Herpes Zoster trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05811754, a study of Herpes Zoster, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- 2,844 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this post-marketing commitment safety study is to evaluate the real-world safety of HZ/su vaccine during pregnancy in immunodeficient or immunosuppressed adult pregnant women between 18 and 49 years of age in the United States. The primary outcome of interest is major congenital malformations (MCMs).
Primary Outcome
The prevalence of MCMs among live births from women with immunocompromised conditions exposed to HZ/su vaccine compared to those not exposed to HZ/su vaccine during pregnancy is evaluated. An MCM (birth defect or structural defect) is defined as a defect, which has either cosmetic or functional significance to the child.
Conditions Studied
Interventions
- OTHER Data collection
Study Locations (1)
Massachusetts
- GSK Investigational Site - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,844 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2028-03-31 |
What the registry record for NCT05811754 still lists
NCT05811754 is an observational study that tracks outcomes without assigning an intervention. Its 2,844 participants enrollment target places it among the larger protocols in the corpus, above the 1,996-participant average among 16 other Herpes Zoster trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.
NCT05811754 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05811754 about?
NCT05811754 is a clinical study titled "Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions". The purpose of this post-marketing commitment safety study is to evaluate the real-world safety of HZ/su vaccine during pregnancy in immunodeficient or immunosuppressed adult pregnant women between 18 and 49 years of age in the United States. The primary outcome of interest is major congenital malfo...
What is the current status of trial NCT05811754?
This trial is currently active not recruiting. The enrollment target is 2,844 participants. The study started on 2022-05-09. Estimated completion is 2028-03-31.
What conditions does trial NCT05811754 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT05811754?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT05811754?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05811754 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05811754's enrollment target sits among peer trials
2,844 4th of 16 higher than 13 of 16 other Herpes Zoster trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
ACTIVE NOT RECRUITING · Phase 3
-
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06150781 · 2,842 participants
Aimovig Pregnancy Exposure Registry
- NCT02273297 · 2,821 participants
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI